Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.

Cereno Scientific AB plans to initiate preclinical disease model studies evaluating CS-585 in antiphospholipid syndrome, a rare autoimmune disease associated with recurrent blood clots and serious cardiovascular complications. The studies will be initiated this year under an ongoing research collaboration with the University of Michigan.

Hangzhou Qihan Biotech Co. Ltd. has obtained IND clearance from the FDA for QT-019C, a universal allogeneic CAR T-cell therapy for autoimmune diseases. QT-019C cell injection is an off-the-shelf allogeneic CAR T-cell therapy engineered from healthy donor leukapheresis products to stably express two distinct CARs targeting CD19 and BCMA.

Ichnos Glenmark Innovation Inc. has announced a new development candidate, ISB-2301, a potentially first-in-class, multispecific immune cell activator for the potential treatment of multiple solid tumor indications. ISB-2301 is a multispecific antibody that targets three tumor-associated antigens to trigger tumor cell death and engages both T and NK cells to activate the immune system. Leveraging the company’s BEAT technology, ISB-2301 is designed to induce potent antibody-dependent cellular cytotoxicity, checkpoint inhibition and a sustained type 1 immune response.

Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit activity and alleviates core behavioral impairments.